Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ACMI - Accumed Inc. -- Ignore unavailable to you. Want to Upgrade?

To: Cisco who wrote (1302)	1/29/1998 12:57:00 PM
From: Frank Buck	Respond to of 1894

Cisco, <<... then I guess it follows we will be seeing AcCell-Savant product before the FDA this year.>> I would hope that we would have an FDA panel meeting on the AcCell/Savant sometime this year. I don't believe I have heard any mention of a time-table in that regard. <<Is this your read or do you think they are planning to become profitable off the TracCell 3000 series?>> The TracCell 3000 still needs to piggy-back on the primary AcCell device. That market may not be fully matured because of the past low sales volume of the primary AcCell systems. A move to sell the TracCell (while thy are awaiting finalization of the Savant) would certainly lessen spending of the finite $6 million. The $6M could last for quite a few quarters were they to offset the spending on continued (Savant) R&D, through sales of the TracCell 3000 and other product inputs that Sakura will be infusing. What are they? The one point that does stand out from the conference call is the remark made about OncoMedics being beyond a developmental stage company. This tells me that the Savant should perhaps be pretty close to fully-developed?? What do you get from that remark? Do you feel we will hear something regarding Nasdaq before the close? BTW: Can you refer me to a good ear-doctor?<g Frank